There is a lot to do, and this grounded focus of making ALS livable helps us hold everyone—ourselves, the FDA, and the research community—accountable to real impacts on real people with ALS and the time it takes to deliver those impacts. This week has been a big step forward for the ALS community, and we will continue urgently working to keep the momentum going.
Following Amylyx’s announcement that it intends to submit a New Drug Application (NDA) for AMX0035, The ALS Association today urges the Food and Drug Administration to approve the treatment for all people with ALS as soon as possible.
We recently talked with Emma Thompson, one of this year’s award recipients, to learn a little more about her personal connection to ALS, what receiving the scholarship means to her, and her future plans in nursing.
We recently talked with Dr. Yichen Li, postdoctoral fellow from the Ichida Lab at the University of Southern California to learn about her unique project focused on the efficacy of suppressing a gene called SYF2 as a therapeutic strategy for diverse forms of ALS.
We recently talked with Ally Halverson, one of this year’s award recipients, to learn a little more about her personal connection to ALS, what receiving the scholarship means to her, and what her future plans are in healthcare.
Thank you to the members of the Time to Diagnosis Working Group for volunteering their time and expertise to develop the thinkALS™ early diagnosis tool and the consensus statement on the benefits of early diagnosis.
Reducing diagnostic delays, from the patient’s initial clinical interaction to confirmed diagnosis of ALS in an ALS clinic, is critical for early initiation of multidisciplinary care, supportive treatments, and standard of care therapies.
Dr. Jeffrey Rothstein, professor of neurology and neuroscience and the founding director of the Robert Packard Center for ALS Research at Johns Hopkins University School of Medicine, and Dr. Alyssa Coyne, a postdoctoral fellow at Johns Hopkins, discuss their recent publication of research identifying a cellular defect common in ALS and what it means for research into the disease going forward.